Date: 2014-09-28
Type of information: Distribution agreement
Compound: AdenoPlus®
Company: Nicox (France) Nitto Medic (Japan)
Therapeutic area: Ophtalmological diseases - Infectious diseases
Type agreement:
Action mechanism: AdenoPlus® is an in vitro diagnostic medical device that aids in the identification of adenovirus to assist in the differential diagnosis of acute conjunctivitis. Nicox in-licensed AdenoPlus® from RPS® in June 2012 and has full exclusive rights to commercialize AdenoPlus® worldwide, except in the United States and Canada.
Disease: acute conjunctivitis
Details: * On August 28, 2014, Nicox, the international ophthalmic company, y announced that it has entered into an exclusive agreement with Nitto Medic, a leading Japanese ophthalmic company, for the distribution in Japan of AdenoPlus®, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. Nicox has worldwide rights outside North America for AdenoPlus® as per an agreement with Rapid Pathogen Screening (RPS®). Under the terms of the agreement, Nitto Medic will become the exclusive distributor of AdenoPlus® in Japan. Nitto Medic will pay a €500,000 upfront payment to Nicox and will purchase the AdenoPlus® devices from Nicox. Nitto Medic will be responsible for obtaining the relevant regulatory approval in Japan before launch. AdenoPlus® is expected to be launched in Japan within the next 18 months, pending regulatory approval.
Financial terms:
Latest news:
